Abdullatip, Alisabri A.

HRN: 18-33-10  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/01/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
05/01/2023
05/07/2023
IV
1.5gm
Q8
Cellulitus Nape Area
Waiting Final Action 
05/01/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
05/01/2023
05/07/2023
IV
600mg
Q6
Cellulitus Nape Area
Waiting Final Action 
05/02/2023
MUPIROCIN 2%, 15G (TUBE)
05/02/2023
05/08/2023
TOPICAL
Apply On Affected Areas
Bid
Nonheaing Wound, Cellulitis Left Nape.
Waiting Final Action 
05/10/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
05/10/2023
05/16/2023
IV
1.5g
Q8
Nonhealing Cellulitis
Waiting Final Action 
05/10/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
05/10/2023
05/16/2023
IV
600mg
Q6
Nonhealing Cellulitis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: